Biopharma 2020: A landmark year and a reset for the future

McKinsey & Company

Biopharma in 2020 has shown what it can achieve when it works at its best. How can the industry build on this renewed sense of purpose in the years ahead? Insights on Pharmaceuticals & Medical Products

O’Dwyer’s PR News: “The Biopharma Communications Balancing Act”

LaVoie Health Science Blog

The post O’Dwyer’s PR News: “The Biopharma Communications Balancing Act” appeared first on LaVoie Health Science. LaVoieHealthScience President and CEO, Donna LaVoie , contributed to the O’Dwyer’s PR News Magazine October issue focused on healthcare and medical public relations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reflections on 2020 ASAP BioPharma Conference: The right mindset is more important than ever

Vantage Partners

Overview The 2020 ASAP BioPharma conference came to a close a month ago and marked another year of bringing together talented and thoughtful strategic alliance professionals to share and reflect on their experiences in this field.

Optimizing Your Alliance Management Operating Model: Considerations from CHI's 2020 Strategic Alliance Management Congress

Vantage Partners

As in the past, this conference featured insightful presentations from leaders across Biopharma alliance management. Vantage Partners was proud to be the premier sponsor for Cambridge HealthTech Institute’s (CHI) 2020 Strategic Alliance Management Congress.

2021 Preview: A 360-Degree Global Market View

LaVoie Health Science Blog

Panelists, including myself as moderator, consisted of industry leaders, including Dr. Alexandra Goll, Managing Director of Biopharma Advisory; Brad Loncar, CEO of Loncar Investments; and Amit Munshi, President, CEO and Board Member of Arena Pharmaceuticals.

Technology Innovations and Virtual Consultations Drive the Healthcare Industry Transformation by 2025

Frost & Sullivan

Biopharma companies should partner with niche AI and data vendors to expedite drug design and development to reduce internal R&D risks for personalized therapies. Global healthcare revenues in 2025 will exceed $2.6 trillion propelled by AI and telehealth, finds Frost & Sullivan.